Bo Tao

Bo Tao

Auto-generated profile, based on publicly available information

Bo Tao

Department of Biomedical Engineering, Yale University, New Haven, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2024 in Nature
Verified
Journal Article
Open access
PDF file
BFBing Feng
Bing Feng
ZBZhiliang Bai
Zhiliang Bai
XZXiaolei Zhou
Xiaolei Zhou
YZYang Zhao
Yang Zhao
YXYu-Qing Xie
Yu-Qing Xie
LTLi Tang
Li Tang
Current cancer immunotherapy predominately focuses on eliciting type 1 immune responses fighting cancer; however, long-term complete remission remains uncommon1,2. A pivotal question arises as to whether type 2 immunity can be orchestrated alongside type 1-centric immunotherapy to achieve enduring response against cancer3,4. Here we show that an interleukin-4 fusion protein (Fc–IL-4), a typical type 2 cytokine, directly acts on CD8+ T cells and enriches functional terminally exhausted CD8+ T (CD8+ TTE) cells in the tumour. Consequently, Fc–IL-4 enhances antitumour efficacy of type 1 immunity-centric adoptive T cell transfer or immune checkpoint blockade therapies and induces durable remission across several syngeneic and xenograft tumour models. Mechanistically, we discovered that Fc–IL-4 signals through both signal transducer and activator of transcription 6 (STAT6) and mammalian target of rapamycin (mTOR) pathways, augmenting the glycolytic metabolism and the nicotinamide adenine dinucleotide (NAD) concentration of CD8+ TTE cells in a lactate dehydrogenase A-dependent manner. The metabolic modulation mediated by Fc–IL-4 is indispensable for reinvigorating intratumoural CD8+ TTE cells. These findings underscore Fc–IL-4 as a potent type 2 cytokine-based immunotherapy that synergizes effectively with type 1 immunity to elicit long-lasting responses against cancer. Our study not only sheds light on the synergy between these two types of immune responses, but also unveils an innovative strategy for advancing next-generation cancer immunotherapy by integrating type 2 immune factors.

25 September 2024 in Nature
Verified
Journal Article
Open access
PDF file
ZBZhiliang Bai
Zhiliang Bai
BFBing Feng
Bing Feng
SMSusan E. McClory
Susan E. McClory
BOBeatriz Coutinho de Oliveira
Beatriz Coutinho de Oliveira
CDCaroline Diorio
Caroline Diorio
RFRong Fan
Rong Fan
Despite a high response rate in chimeric antigen receptor (CAR) T cell therapy for acute lymphocytic leukaemia (ALL)1–3, approximately 50% of patients relapse within the first year4–6, representing an urgent question to address in the next stage of cellular immunotherapy. Here, to investigate the molecular determinants of ultralong CAR T cell persistence, we obtained a single-cell multi-omics atlas from 695,819 pre-infusion CAR T cells at the basal level or after CAR-specific stimulation from 82 paediatric patients with ALL enrolled in the first two CAR T ALL clinical trials and 6 healthy donors. We identified that elevated type 2 functionality in CAR T infusion products is significantly associated with patients maintaining a median B cell aplasia duration of 8.4 years. Analysis of ligand–receptor interactions revealed that type 2 cells regulate a dysfunctional subset to maintain whole-population homeostasis, and the addition of IL-4 during antigen-specific activation alleviates CAR T cell dysfunction while enhancing fitness at both transcriptomic and epigenomic levels. Serial proteomic profiling of sera after treatment revealed a higher level of circulating type 2 cytokines in 5-year or 8-year relapse-free responders. In a leukaemic mouse model, type 2high CAR T cell products demonstrated superior expansion and antitumour activity, particularly after leukaemia rechallenge. Restoring antitumour efficacy in type 2low CAR T cells was attainable by enhancing their type 2 functionality, either through incorporating IL-4 into the manufacturing process or by priming manufactured CAR T products with IL-4 before infusion. Our findings provide insights into the mediators of durable CAR T therapy response and suggest potential therapeutic strategies to sustain long-term remission by boosting type 2 functionality in CAR T cells.

8 May 2025 in Research Square
Verified
Preprint
Open access
PDF file
RFRong Fan
Rong Fan
ABAlev Baysoy
Alev Baysoy
XTXiaolong Tian
Xiaolong Tian
FZFeifei Zhang
Feifei Zhang
PRPaul Renauer
Paul Renauer
SCSidi Chen
Sidi Chen
Spatially resolved in vivo CRISPR screening integrates gene editing with spatial transcriptomics to examine how genetic perturbations alter gene expression within native tissue environments. However, current methods are limited to small perturbation panels and the detection of a narrow subset of protein-coding RNAs. We present Perturb-DBiT, a distinct and versatile approach for the simultaneous co-sequencing of spatial total RNA whole-transcriptome and single-guide RNAs (sgRNAs), base-by-base, on the same tissue section. This method enables unbiased discovery of how genetic perturbations influence RNA regulation, cellular dynamics, and tissue architecture in situ. Applying Perturb-DBiT to a human cancer metastatic colonization model, we mapped large panels of sgRNAs across tumor colonies in consecutive tissue sections alongside their corresponding total RNA transcriptomes. This revealed novel insights into how perturbations affect long non-coding RNA (lncRNA) co-variation, microRNA–mRNA interactions, and global and distinct tRNA alterations in amino acid metabolism linked to tumor migration and growth. By integrating transcriptional pseudotime trajectories, we further uncovered the impact of perturbations on clonal dynamics and cooperation. In an immune-competent syngeneic mouse model, Perturb-DBiT enabled investigation of genetic perturbations within the tumor immune microenvironment, revealing distinct and synergistic effects on immune infiltration and suppression. Perturb-DBiT provides a spatially resolved comprehensive view of how genetic knockouts influence diverse molecular and cellular responses including small and large RNA regulation, tumor proliferation, migration, metastasis, and immune interactions, offering a panoramic perspective on perturbation responses in complex tissues.

1 December 2020 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
BTBo Tao
Bo Tao
JKJan R. Kraehling
Jan R. Kraehling
SGSiavash Ghaffari
Siavash Ghaffari
CRCristina M. Ramirez
Cristina M. Ramirez
SLSungwoon Lee
Sungwoon Lee
WSWilliam C. Sessa
William C. Sessa
Bone morphogenetic protein-9 (BMP-9) is a circulating cytokine that is known to play an essential role in the endothelial homeostasis and the binding of BMP-9 to the receptor activin-like kinase 1 (ALK-1) promotes endothelial cell quiescence. Previously, using an unbiased screen, we identified ALK-1 as a high-capacity receptor for low-density lipoprotein (LDL) in endothelial cells that mediates its transcytosis in a nondegradative manner. Here we examine the crosstalk between BMP-9 and LDL and how it influences their interactions with ALK-1. Treatment of endothelial cells with BMP-9 triggers the extensive endocytosis of ALK-1, and it is mediated by caveolin-1 (CAV-1) and dynamin-2 (DNM2) but not clathrin heavy chain. Knockdown of CAV-1 reduces BMP-9–mediated internalization of ALK-1, BMP-9–dependent signaling and gene expression. Similarly, treatment of endothelial cells with LDL reduces BMP-9–induced SMAD1/5 phosphorylation and gene expression and silencing of CAV-1 and DNM2 diminishes LDL-mediated ALK-1 internalization. Interestingly, BMP-9–mediated ALK-1 internalization strongly re-duces LDL transcytosis to levels seen with ALK-1 deficiency. Thus, BMP-9 levels can control cell surface levels of ALK-1, via CAV-1, to regulate both BMP-9 signaling and LDL transcytosis.

1 October 2017 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
JXJiaqi Xu
Jiaqi Xu
BTBo Tao
Bo Tao
XGXiaohong Guo
Xiaohong Guo
SZShiyi Zhou
Shiyi Zhou
YLYongda Li
Yongda Li
YKYuehai Ke
Yuehai Ke
Persistent activation of macrophages in lungs plays a critical role in the production of matrix metalloproteinases (MMPs) that contributes to the destruction of alveolar walls, a hallmark for pulmonary emphysema. Dysregulated TGF-β1 signaling has been an essential determinant in the elevation of MMPs during the development of emphysema. Nevertheless, the mechanism for this MMP-dependent pathogenesis has yet to be clearly investigated. Recently, we identified an important role for tyrosine phosphatase Src homology domain-containing protein tyrosine phosphatase 2 (Shp2) in regulating the activation of alveolar macrophages. Over a long-term observation period, mice with Shp2 deletion in macrophages (LysMCre:Shp2fl/fl) develop spontaneous, progressive emphysema-like injury in the lungs, characterized by massive destruction of alveolar morphology, interstitial extracellular matrix degradation, and elevated levels of MMPs, particularly, significant increases of macrophage elastase (MMP12) in aged mice. Further analysis demonstrated that MMP12 suppression by TGF-β1 activation was apparently abrogated in LysMCre:Shp2fl/fl mice, whereas the TGF-β1 concentration in the lungs was relatively the same. Mechanistically, we found that loss of Shp2 resulted in attenuated SMAD2/3 phosphorylation and nuclear translocation in response to TGF-β activation, thereby upregulating MMP12 expression in macrophages. Together, our findings define a novel physiological function of Shp2 in TGF-β1/MMP12-dependent emphysema, adding insights into potential etiologies for this chronic lung disorder.

3 June 2017 in International Journal of Digital Earth
Verified
Journal Article
Closed access
SPShufen Pan
Shufen Pan
GCGuangsheng Chen
Guangsheng Chen
WRwei ren
wei ren
SDShree Dangal
Shree Dangal
KBKamaljit Banger
Kamaljit Banger
HTHanqin Tian
Hanqin Tian
Terrestrial ecosystems play a significant role in global carbon and water cycles because of the substantial amount of carbon assimilated through net primary production and large amount of water loss through evapotranspiration (ET). Using a process-based ecosystem model, we investigate the potential effects of climate change and rising atmospheric CO2 concentration on global terrestrial ecosystem water use efficiency (WUE) during the twenty-first century. Future climate change would reduce global WUE by 16.3% under high-emission climate change scenario (A2) and 2.2% under low-emission climate scenario (B1) during 2010–2099. However, the combination of rising atmospheric CO2 concentration and climate change would increase global WUE by 7.9% and 9.4% under A2 and B1 climate scenarios, respectively. This suggests that rising atmospheric CO2 concentration could ameliorate climate change-induced WUE decline. Future WUE would increase significantly at the high-latitude regions but decrease at the low-latitude regions under combined changes in climate and atmospheric CO2. The largest increase of WUE would occur in tundra and boreal needleleaf deciduous forest under the combined A2 climate and atmospheric CO2 scenario. More accurate prediction of WUE requires deeper understanding on the responses of ET to rising atmospheric CO2 concentrations and its interactions with climate.